These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36746102)

  • 1. Generation of a ST3GAL3 null mutant induced pluripotent stem cell (iPSC) line (UKWMPi002-A-3) by CRISPR/Cas9 genome editing.
    Diouf D; Vitale MR; Zöller JEM; Pineau AM; Klopocki E; Hamann C; Ziegler GC; Vanmierlo T; Van den Hove D; Lesch KP
    Stem Cell Res; 2023 Mar; 67():103038. PubMed ID: 36746102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of induced pluripotent stem cell (iPSC) lines carrying a heterozygous (UKWMPi002-A-1) and null mutant knockout (UKWMPi002-A-2) of Cadherin 13 associated with neurodevelopmental disorders using CRISPR/Cas9.
    Vitale MR; Zöller JEM; Jansch C; Janz A; Edenhofer F; Klopocki E; van den Hove D; Vanmierlo T; Rivero O; Nadif Kasri N; Ziegler GC; Lesch KP
    Stem Cell Res; 2021 Mar; 51():102169. PubMed ID: 33486346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
    Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
    Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
    Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
    Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
    Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
    Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
    Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-mediated editing of ACTB in induced pluripotent stem cells: A model for investigating human ACTB loss-of-function and genetic adaptive responses.
    Binder S; Ramachandran H; Haslinger D; Hildebrandt B; Dobner J; Haarmann-Stemmann T; Chiocchetti A; Rossi A
    Stem Cell Res; 2024 Jun; 77():103395. PubMed ID: 38518401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of RUNX1c-eGFP induced pluripotent stem cell, MUSIi012-A-4, using CRISPR/Cas9.
    Srisook P; Laowtammathron C; Lorthongpanich C; Klaihmon P; Terbto P; Waeteekul S; U-Pratya Y; Issaragrisil S
    Stem Cell Res; 2023 Mar; 67():103035. PubMed ID: 36753833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
    Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a homozygous (MCRIi031-A-3) WT1 knockout human iPSC line.
    Pachernegg S; Robevska G; Ferreira LGA; van den Bergen JA; Vlahos K; Howden SE; Sinclair AH; Ayers KL
    Stem Cell Res; 2024 Sep; 79():103494. PubMed ID: 39003885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
    Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a ZEB2 deficient human iPSC line (KICRi002A-4).
    Schuster J; Fatima A; Papadopoulos N; de Guidi C; Sobol M; Dahl N
    Stem Cell Res; 2024 Oct; 80():103521. PubMed ID: 39121652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.
    Hong SG; Yada RC; Choi K; Carpentier A; Liang TJ; Merling RK; Sweeney CL; Malech HL; Jung M; Corat MAF; AlJanahi AA; Lin Y; Liu H; Tunc I; Wang X; Palisoc M; Pittaluga S; Boehm M; Winkler T; Zou J; Dunbar CE
    Mol Ther; 2017 Jan; 25(1):44-53. PubMed ID: 28129126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a heterozygous TPM1-E192K knock-in human induced pluripotent stem cell line using CRISPR/Cas9 system.
    Kang JY; Mun D; Chun Y; Kim H; Yun N; Lee SH; Joung B
    Stem Cell Res; 2022 Aug; 63():102878. PubMed ID: 35917600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.